ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p800.xmlBreast Cancer Risk Reduction and Counseling: Lifestyle, Chemoprevention, and Surgery2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p800.pdf2026-04-18Breast Cancer Risk Reduction and Counseling: Lifestyle, Chemoprevention, and Surgeryhttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p745.xmlShould Resource Constraints Guide Global Guidelines?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p745.pdf2026-04-18Should Resource Constraints Guide Global Guidelines?https://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p753.xmlBarriers to Clinical Trial Participation as Perceived by Oncologists and Patients2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p753.pdf2026-04-18Barriers to Clinical Trial Participation as Perceived by Oncologists and Patientshttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p766.xmlPoint: Combination Versus Single-Agent Chemotherapy: The Argument for Sequential Single Agents2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p766.pdf2026-04-18Point: Combination Versus Single-Agent Chemotherapy: The Argument for Sequential Single Agentshttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p771.xmlCounterpoint: The Argument for Combination Chemotherapy in the Treatment of Metastatic Breast Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p771.pdf2026-04-18Counterpoint: The Argument for Combination Chemotherapy in the Treatment of Metastatic Breast Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p774.xmlBreast Risk Reduction2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p809.xmlDiet and Breast Cancer Risk Reduction2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p809.pdf2026-04-18Diet and Breast Cancer Risk Reductionhttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p851.xmlInterventional Therapies for Cancer Pain Management: Important Adjuvants to Systemic Analgesics2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p851.pdf2026-04-18Interventional Therapies for Cancer Pain Management: Important Adjuvants to Systemic Analgesicshttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p817.xmlThe STAR Trial: Evidence for Raloxifene as a Breast Cancer Risk Reduction Agent for Postmenopausal Women2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p817.pdf2026-04-18The STAR Trial: Evidence for Raloxifene as a Breast Cancer Risk Reduction Agent for Postmenopausal Womenhttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/8/article-p824.xmlAdult Cancer Pain2026-04-18